Top Markets
#1 Black Phoenix Black Phoenix +354.68%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +81.44%
#4 Gold Park Gold Park +61.34%
#5 OpenEden OpenEden +47.65%
#6 Acurast Acurast +33.48%
#7 BasedHype BasedHype +27.22%
#8 Cryptopia Cryptopia +21.54%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
#10 Avantis Avantis +19.86%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Immunotech Laboratories, Inc. Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc.

IMMB
Rank in Stocks #40594
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins... Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Share Price
$0.0002
Last synced: 2026-08-12
Market Cap
$114.99K
Change (1 day)
0.00%
Change (1 year)
100.00%
Country
US
Trade Immunotech Laboratories, Inc. (IMMB)

Category

Healthcare
Earnings for Immunotech Laboratories, Inc. (IMMB)
Earnings in 2026 TTM: 0
According to Immunotech Laboratories, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Immunotech Laboratories, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE